The 2025 Perseid meteor shower won't be ideal. Here are more meteor showers that will be.
The meteor shower began in July and will end near the end of August, but the moon, which was at its peak early morning on Saturday, Aug. 9, could interfere with what is usually a dazzling celestial show.
However, from August to December, six more meteor showers will peak, and three of them will be around the time of the new moon. So our moon won't interfere with them the way it would during its peak, when it looks full.
Here's everything you need to know about the 2025 Perseid meteor shower.
When does the Perseid meteor shower peak?
The Perseid meteor shower is set to peak on the night of Tuesday, August 12, into the early morning of August 13 before sunrise, according to the American Meteor Society's website.
What happens when the Perseids peak?
Usually, during its peak, there will be up to 50 to 75 meteors per hour under ideal conditions, according to the American Meteor Society.
The meteor shower is known to produce very bright meteors, often referred to as fireballs.
However, in 2025, the showers' peak will not meet these ideal conditions because the moon will be too bright, Robert Lunsford, the American Meteor Society's newsletter editor and fireball report coordinator, previously told USA TODAY.
This year's peak will occur around four days after the full moon's peak.
More news: Perseid meteor shower nears its 2025 peak, but viewing might be 'hampered'
More meteor showers in 2025
The meteor showers that have already happened this year are Quadrantids (started in 2024 but peaked in January 2025), Lyrids, Eta Aquariids, and, most recently, the Alpha Capricornids and Southern Delta Aquariids, according to the American Meteor Society website.
The site also states that there are several more happening this year, which include:
Orionids- Thursday, Oct. 2 to Wednesday, Nov. 12; peaks the night of Wednesday, Oct. 22 into the morning of Thursday, Oct. 23. The moon will be 2% full.
Southern Taurids- Monday, Oct. 13 to Thursday, Nov. 27; peaks on the night of Monday, Nov. 3 into the morning of Tuesday, Nov. 4. The moon will be 96% full.
Northern Taurids- Monday, Oct. 13 to Monday, Dec. 1; peaks the night of Saturday, Nov. 8 into the morning of Sunday, Nov. 9. The moon will be 83% full.
Leonids- Monday, Nov. 3 to Tuesday, Dec. 2; peaks the night of Sunday, Nov. 16 into the morning of Monday, Nov. 17. On this night, the moon will be 9% full.
Geminids- Monday, Dec. 1 to Thursday, Dec. 21; peaks on the night of Thursday, Nov. 13 to the morning of Friday, Nov. 14. The moon will be 30% full.
Ursids- Tuesday, Dec. 16 to Friday, Dec. 26; Peaks on the night of Sunday, Dec. 21 to the morning of Monday, Dec. 22. The moon will be 3% full.
The Quadrantids will also begin in 2025, on Friday, Dec. 26, but it will not peak until Saturday, Jan. 3, 2026, when the moon will be 100% full.
Since the Quadrantids start in 2025 but peak in 2026, six more meteor showers are set to reach their peak this year.
Which meteor showers will be the easiest to view this year?
Depending on the weather and cloud coverage, the showers that occur closer to the new moon will receive less interference from the light of the moon, and it will be easier to see, Lunsford previously said.
So, of the six meteor showers that will reach their peak, the Orionids, Leonids, and Ursids will have the least amount of interference from the moon and offer better views.
Where should you face to see the Perseids?
If you're still determined to see the Perseids, "you should face away from the moon," said Lunsford.
While they can come from anywhere, the moon's light could affect your chances of seeing a meteor, but there is a small way to remedy that.
"Lie back, look up, and scan the entire sky," the American Meteor Society stated. "Meteors can appear in any part of the sky, though they will appear to radiate from the constellation Perseus, in the northeast."
Those hoping to see the shower should also do the following, according to the society:
Find a dark location away from light pollution
Give your eyes 20 to 30 minutes to adjust to the dark
Avoid looking at phones or bright lights
For optimal comfort, dress appropriately for the weather, use bug spray, and bring a blanket or a reclining chair.
Do you need any equipment to see the meteor shower?
No, onlookers will not need any equipment to see the meteor shower, according to the society.
However, Lunsford said that those interested in purchasing equipment should steer clear of telescopes that cost less than $500 and recommends purchasing from Celestron.
He advises beginners to opt for a telescope with a lens instead of a mirror, and for those seeking a more affordable option, he recommends a pair of binoculars.
Julia is a trending reporter for USA TODAY. Connect with her on LinkedIn, X, Instagram, and TikTok: @juliamariegz, or email her at jgomez@gannett.com
This article originally appeared on USA TODAY: Perseids 2025: Other meteor showers could offer better views this year
Solve the daily Crossword
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 minutes ago
- Yahoo
ImmunityBio (IBRX) Jumps 14% as on Promising Therapy Candidate Results
We recently published . ImmunityBio, Inc. (NASDAQ:IBRX) is one of the best-performing stocks on Wednesday. ImmunityBio soared by 14.17 percent on Wednesday to close at $2.82 apiece as investors cheered promising early findings from its ongoing trial (QUILT-106) to treat a rare blood cancer type with its therapy candidate. In a statement, ImmunityBio, Inc. (NASDAQ:IBRX) said the first phase of QUILT-106 showed highly promising results in the first two patients with Waldenstrom macroglobulinemia (WM)—a type of non-Hodgkins lymphoma (NHL)—using its CD19 CAR-NK (CD19 t-haNK) natural killer cell therapy. The trial aims to evaluate the safety and efficacy of the cell therapy alone, as well as when it is combined with an existing drug called rituximab. According to ImmunityBio, Inc. (NASDAQ:IBRX), both patients tolerated the therapy candidate without any significant side effects. Notably, all infusions were administered in an outpatient setting. Copyright: katrintimoff / 123RF Stock Photo 'One patient achieved a complete response (CR) with CD19 CAR NK monotherapy, while the second patient achieved CR with CD19 CAR-NK in combination with rituximab. Remission was maintained and is ongoing for six months to date,' ImmunityBio, Inc. (NASDAQ:IBRX) said. While we acknowledge the potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the . Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Gizmodo
9 minutes ago
- Gizmodo
Private Spaceflight Enters the Wild West as Trump Slashes Regulations
President Donald Trump is calling for an ease of regulations for commercial spaceflight and streamlining licensing for rocket launches and reentries. The move highly favors companies like SpaceX but could have negative repercussions on environmental habitats surrounding launchpads. On Wednesday, August 13, Trump signed an executive order intended to bolster the spaceflight industry and increase the overall commercial launch cadence. In it, Trump calls on Transportation Secretary Sean Duffy, who is also currently serving as the acting administrator for NASA, to 'eliminate or expedite…environmental reviews for, and other obstacles to the granting of, launch and reentry licenses and permits.' The order also directs Duffy to 'reevaluate, amend, or rescind' safety requirements and conditions for launch and reentry licenses that were written during Trump's first term as president in 2020. 'By slashing red tape tying up spaceport construction, streamlining launch licenses so they can occur at scale, and creating high-level space positions in government, we can unleash the next wave of innovation,' Duffy said in a statement. 'I look forward to leveraging my dual role at DOT and NASA to make this dream a reality.' The Federal Aviation Administration (FAA) is responsible for granting licenses for space launches and reentries while ensuring public safety and protection of property. For years, SpaceX CEO and founder Elon Musk has expressed dismay over regulatory bodies such as the FAA, complaining that bureaucratic red tape is holding his rocket company back. 'Starships need to fly. The more we fly safely, the faster we learn; the faster we learn, the sooner we realize full and rapid rocket reuse,' SpaceX wrote in a blog last year while awaiting a launch license for Starship's fifth test flight. 'Unfortunately, we continue to be stuck in a reality where it takes longer to do the government paperwork to license a rocket launch than it does to design and build the actual hardware.' On the other hand, local environmental groups in Boca Chica, Texas, the site of SpaceX's Starbase launch facility, have criticized the FAA for regulatory oversight. Starship's inaugural liftoff in April 2023 sent chunks of concrete and metal thousands of feet away from the launchpad, prompting a review of environmental impacts and potential threats to endangered species in the Boca Chica region. Shortly after, conservation groups filed a lawsuit against the FAA for its approval of SpaceX's expanded launch operations in Boca Chica, Texas, without adequate environmental review. The lawsuit claims that the FAA didn't require an in-depth environmental impact statement before approving SpaceX's Starship plans. FAA officials claim that the new order will serve the space economy. 'The FAA strongly supports President Trump's Executive Order to make sure the U.S. leads the growing space economy and continues to lead the world in space transportation and innovation,' FAA Administrator Bryan Bedford said in a statement. 'This order safely removes regulatory barriers so that U.S. companies can dominate commercial space activities.' Environmental experts, on the other hand, disagree. 'This reckless order puts people and wildlife at risk from private companies launching giant rockets that often explode and wreak devastation on surrounding areas,' Jared Margolis, senior attorney for the Center for Biological Diversity, wrote in a statement. 'Bending the knee to powerful corporations by allowing federal agencies to ignore bedrock environmental laws is incredibly dangerous and puts all of us in harm's way.'
Fast Company
39 minutes ago
- Fast Company
Eli Lilly signs $1.3 billion deal with Superluminal to use AI to make obesity medicines
Eli Lilly has signed a deal worth $1.3 billion with privately held Superluminal Medicines to discover and develop small-molecule drugs through AI to treat obesity and other cardiometabolic diseases. Lilly currently dominates the obesity treatment market, which is estimated to be worth $150 billion by the next decade, and is trying to strengthen its foothold in the space through the development of next-generation drugs, acquisitions and partnerships. The deal gives Lilly access to Superluminal's proprietary artificial-intelligence-driven platform to rapidly discover potential drug candidates targeting G-protein-coupled receptors (GPCR)—a class of proteins that can influence a range of physiological processes including metabolism, cell growth and immune responses—the drug developer said on Thursday. In a similar move, Danish rival Novo Nordisk struck a $2.2 billion deal with U.S. biotech Septerna in May to develop oral small-molecule medicines targeting GPCRs for obesity and other cardiometabolic diseases. Lilly has been capitalizing on the overwhelming popularity of the GLP-1 class of medicines, which includes its blockbuster drug Zepbound as well as Novo's Wegovy. It is also developing a keenly watched oral GLP-1 drug, orforglipron, which has failed to meet investors' lofty expectations. The drugmaker teamed up with Hong Kong-listed biotech Laekna last year to develop an experimental obesity drug that aims to help patients lose weight while preserving muscle. Lilly will receive exclusive rights to develop and commercialize drug candidates discovered using Superluminal's platform, the drug developer said. As part of the deal, Superluminal is eligible to receive upfront and milestone payments, an equity investment as well as tiered royalties on net sales, the company said. Boston-based startup Superluminal is developing a wholly owned lead candidate targeting a protein called melanocortin 4 receptor to treat certain rare, genetic forms of obesity and is expected to begin human trials next year. The lead candidate is not part of the deal with Lilly. Superluminal is backed by investors including RA Capital Management, Insight Partners and NVentures, NVIDIA's venture capital arm.
